BTNL2_HUMAN » Butyrophilin-like protein 2

BTNL2_HUMAN » Butyrophilin-like protein 2
Magnify BTNL2_HUMAN » Butyrophilin-like protein 2Enlarged view of image
3D view in GLMol or JMol

gray dot

Download Coordinates

gray dot

Topology in Plasma membrane
Topologyextracellular side
cytoplasmic side
BTNL2_HUMAN » Butyrophilin-like protein 2 » BTL-II;
Hydrophobic Thickness 31.8 ± 3.6 Å
Tilt Angle 8 ± 3°
ΔGtransfer -14.0 kcal/mol
ΔGfold -7.9 kcal/mol
Links UniProtKB, Pfam, Interpro, iHOP, STRING, HGNC
Topology In
TM Segments 4-25 (4-27)
Pathways none
PDB none
OPM none
Complexes none
Interactions none
Domains

AA: 33-142, PDBID: 4F8T, Subunit A, Seq Identity:43%, Immunoglobulin V-set domain

AA: 250-359, PDBID: 4HH8, Subunit A, Seq Identity:53%, Immunoglobulin V-set domain

UniProt annotation for BTNL2_HUMAN » Butyrophilin-like protein 2
FUNCTION: Negative regulator of T-cell proliferation.

TISSUE SPECIFICITY: Expressed in brain, heart, kidney, liver, pancreas, ovary, leukocyte, small intestine, testis and thymus.

INDUCTION: By proinflammatory cytokines such as TNF and IL1B/interleukin-1 beta.

DISEASE: Sarcoidosis 2 (SS2) OMIM: An idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. A nucleotide transition affecting a splice donor site results in the use of an alternative splice site and the production of isoform 3. Individuals expressing isoform 3 have a higher risk for sarcoidosis.

UniProt features for BTNL2_HUMAN » Butyrophilin-like protein 2
CHAIN 1 455 Butyrophilin-like protein 2.
DOMAIN 29 140 Ig-like V-type 1.
DOMAIN 142 234 Ig-like V-type 2.
DOMAIN 236 355 Ig-like V-type 3.
DISULFID 50 124 By similarity.
DISULFID 164 218 By similarity.
DISULFID 267 341 By similarity.
Amino Acid Sequence for BTNL2_HUMAN » Butyrophilin-like protein 2
MVDFPGYNLS GAVASFLFIL LTMKQSEDFR VIGPAHPILA GVGEDALLTC QLLPKRTTMH VEVRWYRSEP STPVFVHRDG VEVTEMQMEE YRGWVEWIEN GIAKGNVALK IHNIQPSDNG QYWCHFQDGN YCGETSLLLK VAGLGSAPSI HMEGPGESGV QLVCTARGWF PEPQVYWEDI RGEKLLAVSE HRIQDKDGLF YAEATLVVRN ASAESVSCLV HNPVLTEEKG SVISLPEKLQ TELASLKVNG PSQPILVRVG EDIQLTCYLS PKANAQSMEV RWDRSHRYPA VHVYMDGDHV AGEQMAEYRG RTVLVSDAID EGRLTLQILS ARPSDDGQYR CLFEKDDVYQ EASLDLKVVS LGSSPLITVE GQEDGEMQPM CSSDGWFPQP HVPWRDMEGK TIPSSSQALT QGSHGLFHVQ TLLRVTNISA VDVTCSISIP FLGEEKIATF SLSGW